Fig. 1.

SH-BC-893 and C2-ceramide cause PP2A-dependent disruptions in endolysosomal trafficking. A, Structures of the PP2A activators FTY720 (Fingolimod), C2-ceramide, SH-BC-893 and the PP2A inhibitor LB-100. B, Surface CD98 levels in FL5.12 cells pre-treated with LB-100 (100 μm) for 1.5 h before addition of DMSO, SH-BC-893 (5 μm), or C2-ceramide (50 μm) for 1 h. Using Student's t test (n.s.) not significant; *, p ≤ 0.05; **, p ≤ 0.01; and ***, p ≤ 0.001 C, DIC microscopy of FL5.12 cells pre-treated with LB-100 (100 μm) for 1.5 h before addition of DMSO, vehicle, SH-BC-893 (5 μm), or C2-ceramide (50 μm) for 2 h.